[ABBV] AbbVie Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NYSE

The data is delayed by 15 minutes.


Price: 62.32 Change: 0.67 (1.08%)
Ext. hours: 62.4 Change: 0.08 (0.13%)

chart ABBV

Refresh chart

Strongest Trends Summary For ABBV

ABBV is in the long-term up 243% in 10 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. Its products include adult and pediatric pharmaceuticals, such as HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; Synthroid to treat hypothyroidism; AndroGel, a daily testosterone replacement therapy; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Kaletra, a prescription anti-HIV-1 medicine used with other anti-HIV-1 medications to increase the chance of treatment response in people with HIV-1; Norvir , a protease inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection; and Lupron, a product for the palliative treatment of advanced prostate cancer. The company also offers TriCor and TRILIPIX, which are fibric acid derivatives that are indicated as adjuncts to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels; Niaspan, an extended release form of niacin that is indicated

Fundamental Ratios
Shares Outstanding EPS4 EPS Growth - 4 Quarters-44.47% EPS Growth - Q/Q-115.9%
EPS Growth - Y/Y Sales Growth - 4 Quarters 2.31% Sales Growth - Q/Q-7.56% P/E17.76
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA6.8% ROE131.88% ROI11.6%
Current Ratio1.39 Quick Ratio1.3 Long Term Debt/Equity2.45 Debt Ratio8.02
Gross Margin79.12% Operating Margin18.33% Net Profit Margin8.89% Dividend Payout Ratio-154.52%
Dividend Yield
Fundamental Data
Cash From Financing Activities-930 M Cash From Investing Activities-873 M Cash From Operating Activities1.59 B Gross Profit4.58 B
Net Profit1.37 B Operating Profit2.11 B Total Assets26.7 B Total Current Assets15.41 B
Total Current Liabilities11.05 B Total Debt15.27 B Total Liabilities25.32 B Total Revenue5.48 B
Technical Data
High 52 week121.94 Low 52 week64.52 Last close99.98 Last change0.75%
RSI36.24 Average true range2.28 Beta1.14 Volume4.37 M
Simple moving average 20 days-2.68% Simple moving average 50 days2.42% Simple moving average 200 days2.97%
Performance Data
Performance Week-2.94% Performance Month0.35% Performance Quart-11.94% Performance Half6.85%
Performance Year50.73% Performance Year-to-date5.21% Volatility daily1.66% Volatility weekly3.7%
Volatility monthly7.59% Volatility yearly26.29% Relative Volume229.33% Average Volume8.94 M
New High New Low


2020-06-06 08:51:00 | If You Like Dividends, You Should Love These 2 Stocks

2020-06-06 08:30:00 | AbbVie Presents Data Showing RINVOQ™ upadacitinib Meets Primary and Key Secondary Endpoints in Phase 3 Head-to-Head Study Versus ORENCIA abatacept in Rheumatoid Arthritis Patients

2020-06-05 16:18:57 | Pharma Giant AbbVie Enters Ring With A Potential Coronavirus Treatment

2020-06-05 12:10:00 | AbbVie Enters the Race to Develop New COVID-19 Treatments

2020-06-05 10:31:02 | The Market Timing Secrets No One Talks About - June 05, 2020

2020-06-05 10:03:02 | The Zacks Analyst Blog Highlights: AbbVie, Amkor Technology, Calix, The Hain Celestial Group and Acacia Communications

2020-06-05 09:09:01 | Pharma Stock Roundup: LLY Coronavirus Antibody Phase I Study Initiation, FDA Approvals

2020-06-05 07:34:09 | The Daily Biotech Pulse: Adamas Rallies On FDA Acceptance, Oxford Immunotech Reportedly Gets $400M Bid

2020-06-05 06:00:00 | AbbVie, Harbour BioMed, Utrecht University and Erasmus Medical Center Announce Collaboration to Develop Monoclonal Antibody Therapy to Prevent and Treat COVID-19

2020-06-04 17:11:02 | Biotech Stock To Watch: Why This Leader Could Be Poised For Another Run

2020-06-04 11:30:03 | Is AbbVie ABBV Outperforming Other Medical Stocks This Year?

2020-06-04 10:50:02 | Top Ranked Value Stocks to Buy for June 4th

2020-06-04 10:39:37 | AbbVie Follows Up After Reversal

2020-06-04 10:07:02 | Signs That Your Trading Will Ruin Your Retirement - June 04, 2020

2020-06-04 08:30:00 | New Long-term Data from RINVOQ™ upadacitinib, 15 mg Phase 3 Studies in Rheumatoid Arthritis Presented at 2020 Annual European E-Congress of Rheumatology EULAR

2020-06-04 07:24:11 | 50-Day Rally Spells Good Times for Wall Street: 5 Solid Buys

2020-06-04 07:00:00 | Dr. Keshav K. Singh Joins Allergan Aesthetics Science Of AgingSM Faculty

2020-06-03 12:37:04 | Bristol Myers' Zeposia Meet Goals in Ulcerative Colitis Study

2020-06-03 11:50:03 | Is AbbVie ABBV Stock Undervalued Right Now?

2020-06-03 08:57:12 | Increased Earnings Estimates Seen for AbbVie ABBV: Can It Move Higher?

2020-06-03 08:00:00 | AbbVie to Present at the Virtual Goldman Sachs 41st Annual Global Healthcare Conference

2020-06-03 07:02:00 | Why Editas Medicine Is Now the CRISPR Stock to Really Watch

2020-06-02 17:45:09 | AbbVie ABBV Gains But Lags Market: What You Should Know

2020-06-02 16:23:25 | MARKETS: Dow surges into the close, up 268 points — YF Premium is bullish on Abbvie ABBV

2020-06-02 16:00:42 | 7 High-Dividend Stocks With Durable Distributions

2020-06-02 15:28:00 | Biosimilars of Humira Have Saved Europe a Bundle, Study Says

2020-06-02 14:50:58 | Pharma Large And Mid-Caps Race Against COVID-19

2020-06-02 14:20:00 | AbbVie Invests in a Cancer Drug - How to Trade the Stock

2020-06-02 12:27:00 | These 2 charts show why record-high stock valuations shouldn’t worry investors

2020-06-02 11:43:03 | AbbVie Seeks US and EU Nods for Rinvoq for Psoriatic Arthritis

2020-06-02 11:22:00 | AbbVie Stock Affirmed Outperform at RBC on Allergan Potential

2020-06-02 10:53:25 | AstraZeneca Ranked Most Inventive, Roche Most Innovative

2020-06-02 10:36:00 | AbbVie Stock Has Room to Run After Allergan Merger, Argus Says

2020-06-02 10:30:02 | The Zacks Analyst Blog Highlights: Tencent, Abbvie and Reckitt Benckiser

2020-06-02 09:16:00 | Buy Lilly, AbbVie and Merck Stocks, J.P. Morgan Says, but Pfizer Is Still Expensive

2020-06-02 08:03:00 | 3 Stocks With Dividends Yielding More Than 3%

2020-06-02 04:12:44 | AbbVie Seeks Rinvoq Approval For Psoriatic Arthritis In US, Europe

2020-06-02 03:31:39 | Revance, Mylan Move Forward With Botox Rival; Analyst Sees Long Path Ahead

2020-06-01 15:28:07 | 3 Strong Pharmaceutical and Biotech Stocks to Buy for Coronavirus Immunity

2020-06-01 12:25:00 | AbbVie Unveils Deal for Potential Tumor-Fighting Drug

2020-06-01 11:46:03 | AbbVie Gets FDA Nod for Oriahnn to Control Menstrual Bleeding

2020-06-01 11:40:00 | AbbVie Submits Regulatory Applications to FDA and EMA for RINVOQ™ upadacitinib for the Treatment of Adults with Active Psoriatic Arthritis

2020-06-01 10:03:02 | Lilly's Cyramza Gets FDA Approval for First-Line Lung Cancer

2020-06-01 08:30:00 | Allergan Aesthetics Launches Dedicated Multi-Channel Campaign To Contact Patients Who May Not Be Aware Of The BIOCELL® Recall And To Improve Tracking Information For U.S. Breast Implant Patients

2020-06-01 08:03:26 | Drugmaker Abbvie Teams Up With Jacobio To Develop Cancer Inhibitor

2020-06-01 01:00:00 | AbbVie and Jacobio Announce Strategic Collaboration to Advance SHP2 Inhibitors

2020-05-31 11:30:03 | Why Is AbbVie ABBV Up 12.7% Since Last Earnings Report?

2020-05-29 18:47:11 | Gilead Continues to Build Cancer Franchise

2020-05-29 16:13:00 | FDA Approves the First Oral Medication for the Management of Heavy Menstrual Bleeding Due to Uterine Fibroids in Pre-menopausal Women

2020-05-28 17:06:04 | Why it may take the travel industry a few years to get back to normal